Policy & Regulation
Neuraptive Therapeutics names Evan Tzanis as EVP
12 June 2019 -

Neuraptive Therapeutics Inc, a provider of therapies for nerve repairs, revealed on Tuesday the election of Evan Tzanis as executive vice president, head of its R&D.

In the company's R&D department, Tzanis will oversee all research and development activities, including the preclinical, clinical, medical and regulatory of its franchise therapeutic product, AxoFuse.

More recently, Tzanis has served as chief development officer at Paratek Pharmaceuticals, where he led all development activities of omadacycline (Nuzyra), as well as head of development operations and biometrics at Endo Pharmaceuticals for its clinical and project management.

Earlier in his career, Tzanis had roles of increasing responsibilities at Quintiles (now IQUVIA), Wyeth Pharmaceuticals and Pfizer.